Hans Bishop, Grail CEO (Victor J. Blue/Bloomberg via Getty Images)
May 7, 2020 09:00 AM EDT
Financing
Startups

Blood test for can­cer de­tec­tion com­pa­ny Grail rakes in $390M in lat­est round

Natalie Grover

Reporter

Just over a week af­ter Third Rock-backed Thrive un­veiled ‘re­al world’ da­ta from a large study eval­u­at­ing the abil­i­ty of its blood test to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times